Drug · DIN 02238683
ACTACEL
No: cancelled before it was sold
Authorized, then cancelled before it was ever sold in Canada.
Status Cancelled Pre Market since March 27, 2020.
- Drug Identification Number (DIN)
- 02238683
- Company (DIN owner)
- Sanofi Vaccines Canada Ltd.Toronto, Ontario, Canada
- Schedule
- Schedule D
- Dosage form
- Liquid
- Route
- Intramuscular
- Therapeutic class (ATC)
- Hemophilus influenzae B, combinations with pertussis and toxoids J07AG52
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PERTUSSIS TOXOID | 10 MCG | 0.5 ML |
| FILAMENTOUS HAEMAGGLUTININ | 5 MCG | 0.5 ML |
| FIMBRIAE | 5 MCG | 0.5 ML |
| PERTACTIN | 3 MCG | 0.5 ML |
| DIPHTHERIA TOXOID | 15 LF | 0.5 ML |
| TETANUS TOXOID | 5 LF | 0.5 ML |
| POLYRIBOSE RIBITOL PHOSPHATE POLYSACCHARIDE (PRP) | 10 MCG | 0.5 ML |
| TETANUS PROTEIN | 30 MCG | 0.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 8, 2005: NOC 7605New Drug Submission (NDS) · Manufacturer name change
- April 4, 2000: NOC 973New Drug Submission (NDS)
- August 31, 1998: NOC 5971New Drug Submission (NDS)